JP2020524996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524996A5 JP2020524996A5 JP2019569226A JP2019569226A JP2020524996A5 JP 2020524996 A5 JP2020524996 A5 JP 2020524996A5 JP 2019569226 A JP2019569226 A JP 2019569226A JP 2019569226 A JP2019569226 A JP 2019569226A JP 2020524996 A5 JP2020524996 A5 JP 2020524996A5
- Authority
- JP
- Japan
- Prior art keywords
- chemokine
- composition
- encoded
- viral vector
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013603 viral vector Substances 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 34
- 102100039291 Geranylgeranyl pyrophosphate synthase Human genes 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 27
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 102000019034 Chemokines Human genes 0.000 claims description 20
- 108010012236 Chemokines Proteins 0.000 claims description 20
- 108091032955 Bacterial small RNA Proteins 0.000 claims description 18
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims description 18
- 230000037361 pathway Effects 0.000 claims description 18
- 108010007508 Farnesyltranstransferase Proteins 0.000 claims description 16
- 102000007317 Farnesyltranstransferase Human genes 0.000 claims description 16
- 108010026318 Geranyltranstransferase Proteins 0.000 claims description 16
- 101000888406 Homo sapiens Geranylgeranyl pyrophosphate synthase Proteins 0.000 claims description 16
- 102100027665 Isopentenyl-diphosphate Delta-isomerase 1 Human genes 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 102000001902 CC Chemokines Human genes 0.000 claims description 8
- 108010040471 CC Chemokines Proteins 0.000 claims description 8
- 101710153681 Isopentenyl-diphosphate Delta-isomerase 1 Proteins 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- -1 IL-1β Proteins 0.000 claims description 7
- 108700011259 MicroRNAs Proteins 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 102100027154 Butyrophilin subfamily 3 member A3 Human genes 0.000 claims description 5
- 101000984916 Homo sapiens Butyrophilin subfamily 3 member A3 Proteins 0.000 claims description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 claims description 4
- 108050005711 C Chemokine Proteins 0.000 claims description 4
- 102000017483 C chemokine Human genes 0.000 claims description 4
- 108050006947 CXC Chemokine Proteins 0.000 claims description 4
- 102000019388 CXC chemokine Human genes 0.000 claims description 4
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 4
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 4
- 229960004276 zoledronic acid Drugs 0.000 claims description 4
- 101710091045 Envelope protein Proteins 0.000 claims description 3
- 101710188315 Protein X Proteins 0.000 claims description 3
- 102100021696 Syncytin-1 Human genes 0.000 claims description 3
- 102100027138 Butyrophilin subfamily 3 member A1 Human genes 0.000 claims description 2
- 102100027155 Butyrophilin subfamily 3 member A2 Human genes 0.000 claims description 2
- 101000984934 Homo sapiens Butyrophilin subfamily 3 member A1 Proteins 0.000 claims description 2
- 101000984917 Homo sapiens Butyrophilin subfamily 3 member A2 Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 108700004026 gag Genes Proteins 0.000 claims description 2
- 108700004029 pol Genes Proteins 0.000 claims description 2
- 108700004030 rev Genes Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 29
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 claims 6
- 229940122361 Bisphosphonate Drugs 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 description 14
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023118187A JP2023133396A (ja) | 2017-06-16 | 2023-07-20 | ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| JP2025048283A JP2025089431A (ja) | 2017-06-16 | 2025-03-24 | ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521274P | 2017-06-16 | 2017-06-16 | |
| US62/521,274 | 2017-06-16 | ||
| US201862633461P | 2018-02-21 | 2018-02-21 | |
| US62/633,461 | 2018-02-21 | ||
| PCT/US2018/037924 WO2018232359A1 (en) | 2017-06-16 | 2018-06-15 | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118187A Division JP2023133396A (ja) | 2017-06-16 | 2023-07-20 | ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524996A JP2020524996A (ja) | 2020-08-27 |
| JP2020524996A5 true JP2020524996A5 (enExample) | 2021-07-29 |
Family
ID=64660752
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569226A Pending JP2020524996A (ja) | 2017-06-16 | 2018-06-15 | ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| JP2023118187A Withdrawn JP2023133396A (ja) | 2017-06-16 | 2023-07-20 | ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| JP2025048283A Pending JP2025089431A (ja) | 2017-06-16 | 2025-03-24 | ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118187A Withdrawn JP2023133396A (ja) | 2017-06-16 | 2023-07-20 | ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| JP2025048283A Pending JP2025089431A (ja) | 2017-06-16 | 2025-03-24 | ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200181645A1 (enExample) |
| EP (1) | EP3638779A4 (enExample) |
| JP (3) | JP2020524996A (enExample) |
| KR (1) | KR20200018586A (enExample) |
| CN (1) | CN110770338A (enExample) |
| CA (1) | CA3064442A1 (enExample) |
| IL (1) | IL271274A (enExample) |
| WO (1) | WO2018232359A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| CA3011529A1 (en) | 2016-01-15 | 2017-07-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta t-cells |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS |
| IL300730A (en) | 2016-07-08 | 2023-04-01 | American Gene Tech Int Inc | Pre-HIV vaccine and immunotherapy |
| JP7176756B2 (ja) | 2016-07-21 | 2022-11-22 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | パーキンソン病を処置するためのウイルスベクター |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| WO2020097049A1 (en) | 2018-11-05 | 2020-05-14 | American Gene Technologies International Inc. | Vector system for expressing regulatory rna |
| CN114555785B (zh) * | 2019-10-17 | 2024-12-06 | 香港大学 | 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法 |
| EP4090432A4 (en) * | 2020-01-15 | 2024-04-17 | The Regents Of The University Of California | Compositions and methods for altering gamma delta t cell activity |
| CN115551532A (zh) * | 2020-03-03 | 2022-12-30 | 美国基因技术国际有限公司 | 在淋巴细胞中按需表达外源性因子以治疗hiv |
| CN113842459B (zh) * | 2021-01-18 | 2023-01-06 | 陈晓文 | 一种病理性血管生成抑制剂及其用途 |
| KR20230147060A (ko) * | 2021-01-21 | 2023-10-20 | 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 | 조작된 nk 세포 및 암 치료 방법 |
| JP2024507735A (ja) * | 2021-02-08 | 2024-02-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ブチロフィリンサブファミリー3メンバーa1(btn3a1、cd277)の制御 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011133687A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for inhibition of beta2-adrenergic receptor degradation |
| US9745631B2 (en) * | 2011-12-20 | 2017-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for diagnosing and treating oncogenic kras-associated cancer |
| WO2014117050A2 (en) * | 2013-01-26 | 2014-07-31 | Mirimus, Inc. | Modified mirna as a scaffold for shrna |
| CA3011529A1 (en) * | 2016-01-15 | 2017-07-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta t-cells |
-
2018
- 2018-06-15 US US16/614,682 patent/US20200181645A1/en active Pending
- 2018-06-15 EP EP18817253.0A patent/EP3638779A4/en active Pending
- 2018-06-15 CN CN201880039828.4A patent/CN110770338A/zh active Pending
- 2018-06-15 JP JP2019569226A patent/JP2020524996A/ja active Pending
- 2018-06-15 CA CA3064442A patent/CA3064442A1/en active Pending
- 2018-06-15 KR KR1020207000631A patent/KR20200018586A/ko not_active Ceased
- 2018-06-15 WO PCT/US2018/037924 patent/WO2018232359A1/en not_active Ceased
-
2019
- 2019-12-09 IL IL271274A patent/IL271274A/en unknown
-
2023
- 2023-07-20 JP JP2023118187A patent/JP2023133396A/ja not_active Withdrawn
-
2025
- 2025-03-24 JP JP2025048283A patent/JP2025089431A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524996A5 (enExample) | ||
| JP2019501661A5 (enExample) | ||
| TWI704226B (zh) | 重組溶瘤病毒組合物及其用途 | |
| JP2025089431A (ja) | ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 | |
| AU2017207906B2 (en) | Methods and compositions for the activation of gamma-delta T-cells | |
| Zhou et al. | SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans | |
| Reinhard et al. | Vpx rescue of HIV-1 from the antiviral state in mature dendritic cells is independent of the intracellular deoxynucleotide concentration | |
| JP2019520841A5 (enExample) | ||
| WO2010060967A2 (en) | Compositions and methods for treating retrovirus infections | |
| Huang et al. | HIV-1-induced miR-146a attenuates monocyte migration by targeting CCL5 in human primary macrophages | |
| KR20220125806A (ko) | 재조합 백시니아 바이러스 | |
| Zhu et al. | Immune escape of avian oncogenic Marek’s disease herpesvirus and antagonistic host immune responses | |
| AU2020454342A1 (en) | Construct and use thereof | |
| US20150307897A1 (en) | Non-viral vector | |
| US20200056203A1 (en) | Treating Animal Cancers Through Programmed Cancer Cell Death | |
| CN114761562A (zh) | 经修饰的细胞外包膜病毒 | |
| CN101654686A (zh) | 一种可用于艾滋病基因治疗的多靶点siRNA重组慢病毒载体 | |
| CN115418356B (zh) | 一种表达i型干扰素的hsv-1溶瘤病毒 | |
| JP7227654B2 (ja) | 固形癌及び微生物感染を治療するための方法及び組成物 | |
| Monet et al. | The emergence of the next-generation vaccines | |
| JP5699093B2 (ja) | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 | |
| US20190169636A1 (en) | Directing Cancer Cells to Self-Destruct Through Vectoring Engineered Viruses | |
| JP2006515172A (ja) | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 | |
| EP1003492A2 (en) | Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins | |
| US20230355691A1 (en) | Novel recombinant vaccinia virus and use thereof |